Stoke Therapeutics lowered 2025 EPS forecasts amid losses and pipeline issues, despite revenue beat.

HC Wainwright and Cantor Fitzgerald lowered their 2025 EPS estimates for Stoke Therapeutics to $0.04 and $0.03, respectively, citing ongoing pipeline challenges and a recent quarterly earnings miss, with the company reporting a $0.65 loss per share, below the $0.54 consensus. Despite revenue of $10.63 million, surpassing estimates, the firm continues to operate at a loss, with full-year losses projected through 2027. The stock, trading at $22.47 with a $1.28 billion market cap, has a consensus "Moderate Buy" rating and a $31.00 target, though some analysts maintain "buy" ratings with higher targets. Insider selling and mixed institutional activity reflect cautious investor sentiment.